Home / Going-concern warnings / Outlook Therapeutics, Inc.
Filed 2026-02-17 · Form 10-Q · Accession 0001104659-26-016554 nano
Price before filing: $0.49 (2026-02-13 close, split/dividend-adjusted)
Market cap at flag: $34.6M (2026-02-17) · Latest: $12.4M (2026-10-16)
| Window | OTLK | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -31.4% | -3.2% | -28.2% | 2026-03-19 |
| 90 days | -53.2% | +8.6% | -61.9% | 2026-05-18 |
| 180 days | +37.2% | +13.9% | +23.2% | 2026-08-17 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Notes to Unaudited Interim Consolidated Financial Statements ​ As a result, there is substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-12-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.